Biomedicines (May 2024)

Optimizing Recombinant Cas9 Expression: Insights from <i>E. coli</i> BL21(DE3) Strains for Enhanced Protein Purification and Genome Editing

  • Shilpi Agrawal,
  • Made Harumi Padmaswari,
  • Abbey L. Stokes,
  • Daniel Maxenberger,
  • Morgan Reese,
  • Adila Khalil,
  • Christopher E. Nelson

DOI
https://doi.org/10.3390/biomedicines12061226
Journal volume & issue
Vol. 12, no. 6
p. 1226

Abstract

Read online

The CRISPR-Cas9 system is a revolutionary tool in genetic engineering, offering unprecedented precision and efficiency in genome editing. Cas9, an enzyme derived from bacteria, is guided by RNA to edit DNA sequences within cells precisely. However, while CRISPR-Cas9 presents notable benefits and encouraging outcomes as a molecular tool and a potential therapeutic agent, the process of producing and purifying recombinant Cas9 protein remains a formidable hurdle. In this study, we systematically investigated the expression of recombinant SpCas9-His in four distinct Escherichia coli (E. coli) strains (Rosetta2, BL21(DE3), BL21(DE3)-pLysS, and BL21(DE3)-Star). Through optimization of culture conditions, including temperature and post-induction time, the BL21(DE3)-pLysS strain demonstrated efficient SpCas9 protein expression. This study also presents a detailed protocol for the purification of recombinant SpCas9, along with detailed troubleshooting tips. Results indicate successful SpCas9 protein expression using E. coli BL21(DE3)-pLysS at 0.5 mM IPTG concentration. Furthermore, the findings suggest potential avenues for further enhancements, paving the way for large-scale Cas9 production. This research contributes valuable insights into optimizing E. coli strains and culture conditions for enhanced Cas9 expression, offering a step forward in the development of efficient genome editing tools and therapeutic proteins.

Keywords